Vantage logo

Safety scare knocks Novartis

Heightened Beovu safety concerns could turn into a big problem for Novartis, while rival Regeneron will make the most of any uncertainty.

Vantage logo

Esperion shifts to show not tell

After spending years insisting that its cholesterol-lowering medicine has a place between statins and PCSK9 inhibitors, Esperion must now prove it.

Vantage logo

The big cap empire strikes back

If the first three quarters of 2019 were dominated by pricing fears, the last saw a remarkable comeback for biopharma.

Vantage logo

Ash 2019 winners and losers

Data and M&A lifts buoyant biopharma companies from Fate Therapeutics to Rocket, though on share price gain Forty Seven wins Ash 2019.